
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type from the provided ranked marker list, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **AREG (Amphiregulin):** A member of the epidermal growth factor (EGF) family, involved in cell proliferation and differentiation.<br>- **TGM2 (Transglutaminase 2):** Involved in apoptosis, cell adhesion, and extracellular matrix stabilization.<br>- **ITGA2 (Integrin alpha-2):** Plays a role in cell adhesion and recognition in various processes including embryogenesis, hemostasis, tissue repair, immune response, and metastatic spread of tumor cells.<br>- **AQP3 (Aquaporin 3):** A water channel protein, also facilitates the transport of glycerol and other small solutes.<br>- **TNFRSF12A (Tumor necrosis factor receptor superfamily member 12A):** Involved in the regulation of cell death and survival.<br>- **S100A6, S100A14, S100A16:** Members of the S100 family, involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation.<br>- **CXCL1, CXCL8, CXCL3:** Chemokines involved in the recruitment of immune cells to sites of inflammation.<br>- **HIF1A (Hypoxia-inducible factor 1-alpha):** A transcription factor that responds to changes in available oxygen in the cellular environment, crucial for cellular response to hypoxia.<br><br>### Step 2: List the Key Cell Type Markers<br>- **KRT7 (Keratin 7):** Typically expressed in epithelial cells, particularly in glandular and transitional epithelia.<br>- **ITGB6 (Integrin beta-6):** Often expressed in epithelial cells and involved in epithelial cell adhesion and signaling.<br>- **ANXA3 (Annexin A3):** Expressed in epithelial cells and involved in membrane-related events along exocytotic and endocytotic pathways.<br>- **TM4SF1 (Transmembrane 4 L six family member 1):** Expressed in epithelial cells and associated with cell proliferation and motility.<br>- **TACSTD2 (Tumor-associated calcium signal transducer 2):** Also known as Trop2, a marker for epithelial cells, particularly in cancerous tissues.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and PanglaoDB, these markers are cross-referenced to confirm their association with specific cell types. The presence of epithelial markers like KRT7, ITGB6, and TACSTD2 strongly suggests an epithelial origin, likely from glandular tissue.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of epithelial markers (KRT7, ITGB6, TACSTD2) and functional markers associated with epithelial cell functions (AREG, ITGA2, TM4SF1), the most probable general cell type is **epithelial cells**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal Epithelial Cells:** Given the expression of KRT7 and TACSTD2, which are often found in luminal epithelial cells of the breast.<br>2. **Basal Epithelial Cells:** Although less likely due to the lack of specific basal markers, the presence of integrins could suggest a basal phenotype.<br>3. **Cancerous Epithelial Cells:** The presence of markers like TACSTD2 and AREG, which are often upregulated in cancer, suggests a cancerous epithelial subtype.<br><br>The most likely subtype, considering the context of breast cancer tissue and the expression of these markers, is **cancerous luminal epithelial cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of epithelial cells, specifically cancerous luminal epithelial cells. This conclusion is supported by the expression of key epithelial markers such as KRT7, ITGB6, and TACSTD2, along with functional markers like AREG and ITGA2, which are associated with epithelial cell proliferation and cancer.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    To validate the annotation result, let's follow the outlined steps:<br><br>### Step 1: Marker Consistency<br>- The provided marker list includes: AREG, TGM2, ITGA2, AQP3, TNFRSF12A, S100A6, S100A14, S100A16, CXCL1, CXCL8, CXCL3, HIF1A, KRT7, ITGB6, ANXA3, TM4SF1, and TACSTD2.<br>- All markers mentioned in the annotation result are present in the provided marker list.<br>- The markers are consistent with the identified cell type, as they are associated with epithelial cells and functions related to epithelial cell biology, such as proliferation, adhesion, and cancer.<br><br>### Step 2: Mixed Cell Type Consideration<br>- The annotation suggests a primary identification of epithelial cells, specifically cancerous luminal epithelial cells.<br>- The presence of markers like KRT7, ITGB6, and TACSTD2 strongly supports an epithelial origin.<br>- There is no strong evidence of multiple distinct cell types based on the high-ranking markers provided. The markers predominantly support an epithelial cell type, particularly in a cancerous context.<br><br>### Conclusion<br>The annotation result is consistent with the provided marker list and the identified cell type. There is no indication of a mixed cell type population that requires further investigation.<br><br>Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>cancerous luminal epithelial cells</li><li>luminal epithelial cells</li><li>basal epithelial cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>cancerous epithelial cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a thorough and methodical approach to identifying the cell type from the given marker list. The analysis correctly identifies the main cell type as epithelial cells, which is consistent with the presence of markers such as KRT7, ITGB6, and TACSTD2. These markers are well-known to be associated with epithelial cells, particularly in the context of breast tissue, which aligns with the cluster origin of human breast cancer.<br><br>The annotation also effectively considers the functional roles of various markers, such as AREG and ITGA2, which are involved in cell proliferation and adhesion, further supporting the identification of epithelial cells. The inclusion of cancer-related markers like TACSTD2 and AREG suggests a cancerous epithelial subtype, which is appropriate given the context of breast cancer.<br><br>The analysis does a commendable job of balancing the consideration of multiple markers, rather than over-focusing on a specific one. It cross-references known databases to validate the marker associations, which adds credibility to the annotation. The identification of sub cell types, such as cancerous luminal epithelial cells, is logical and well-supported by the marker expression patterns.<br><br>However, there are a few areas where the analysis could be improved. While the annotation considers the rank of the markers, it could place more emphasis on the highest-ranking markers, as these are typically more indicative of the cell type. Additionally, the analysis could explore the possibility of mixed cell populations more thoroughly, even though the validation step suggests a single cell type predominance.<br><br>Overall, the annotation provides a comprehensive view of the cell types present, with a strong focus on epithelial cells in a cancerous context. There are no obvious misclassifications, and the analysis captures the general picture of the cell populations effectively.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    